Real-world use of mycophenolate mofetil in inflammatory bowel disease : Results from the ENEIDA registry
Copyright © 2021 Elsevier Ltd. All rights reserved..
BACKGROUND: Studies to evaluate the use of mycophenolate mofetil (MMF) in inflammatory bowel disease (IBD) are limited after the appearance of biological treatments.
AIMS: Our primary objective was to evaluate the effectiveness and safety of MMF in IBD.
METHODS: IBD patients who had received MMF were retrieved from the ENEIDA registry. Clinical activity as per the Harvey-Bradshaw Index (HBI), partial Mayo score (pMS), physician global assessment (PGA) and C-reactive protein (CRP) were reviewed at baseline, at 3 and 6 months, and at final follow-up. Adverse events and causes of treatment discontinuation were documented.
RESULTS: A total of 83 patients were included (66 Crohn's disease, 17 ulcerative colitis), 90% of whom had previously received other immunosuppressants. In 61% of patients systemic steroids were used at initiation of MMF, and in 27.3% biological agents were co-administered with MMF. Overall clinical effectiveness was observed in 64.7% of the population. At the end of treatment, 45.6% and 19.1% of subjects showed remission and clinical response, respectively. MMF treatment was maintained for a median of 28.9 months (IQR: 20.4-37.5).
CONCLUSION: Our study suggests, in the largest cohort to date, that MMF may be an effective alternative to thiopurines and methotrexate in IBD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver - 54(2022), 5 vom: 05. Mai, Seite 635-641 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hernández-Camba, A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Crohn's disease |
|---|
| Anmerkungen: |
Date Completed 02.05.2022 Date Revised 02.05.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.dld.2021.10.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333988663 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333988663 | ||
| 003 | DE-627 | ||
| 005 | 20231225222757.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.dld.2021.10.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1113.xml |
| 035 | |a (DE-627)NLM333988663 | ||
| 035 | |a (NLM)34862115 | ||
| 035 | |a (PII)S1590-8658(21)00807-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hernández-Camba, A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Real-world use of mycophenolate mofetil in inflammatory bowel disease |b Results from the ENEIDA registry |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.05.2022 | ||
| 500 | |a Date Revised 02.05.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 Elsevier Ltd. All rights reserved. | ||
| 520 | |a BACKGROUND: Studies to evaluate the use of mycophenolate mofetil (MMF) in inflammatory bowel disease (IBD) are limited after the appearance of biological treatments | ||
| 520 | |a AIMS: Our primary objective was to evaluate the effectiveness and safety of MMF in IBD | ||
| 520 | |a METHODS: IBD patients who had received MMF were retrieved from the ENEIDA registry. Clinical activity as per the Harvey-Bradshaw Index (HBI), partial Mayo score (pMS), physician global assessment (PGA) and C-reactive protein (CRP) were reviewed at baseline, at 3 and 6 months, and at final follow-up. Adverse events and causes of treatment discontinuation were documented | ||
| 520 | |a RESULTS: A total of 83 patients were included (66 Crohn's disease, 17 ulcerative colitis), 90% of whom had previously received other immunosuppressants. In 61% of patients systemic steroids were used at initiation of MMF, and in 27.3% biological agents were co-administered with MMF. Overall clinical effectiveness was observed in 64.7% of the population. At the end of treatment, 45.6% and 19.1% of subjects showed remission and clinical response, respectively. MMF treatment was maintained for a median of 28.9 months (IQR: 20.4-37.5) | ||
| 520 | |a CONCLUSION: Our study suggests, in the largest cohort to date, that MMF may be an effective alternative to thiopurines and methotrexate in IBD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Crohn's disease | |
| 650 | 4 | |a Inflammatory bowel disease | |
| 650 | 4 | |a Mycophenolate mofetil | |
| 650 | 4 | |a Ulcerative colitis | |
| 650 | 7 | |a Mycophenolic Acid |2 NLM | |
| 650 | 7 | |a HU9DX48N0T |2 NLM | |
| 700 | 1 | |a Arranz, L |e verfasserin |4 aut | |
| 700 | 1 | |a Vera, I |e verfasserin |4 aut | |
| 700 | 1 | |a Carpio, D |e verfasserin |4 aut | |
| 700 | 1 | |a Calafat, M |e verfasserin |4 aut | |
| 700 | 1 | |a Lucendo, A J |e verfasserin |4 aut | |
| 700 | 1 | |a Taxonera, C |e verfasserin |4 aut | |
| 700 | 1 | |a Marín, S |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia, M J |e verfasserin |4 aut | |
| 700 | 1 | |a Marín, G Suris |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez, E Sánchez |e verfasserin |4 aut | |
| 700 | 1 | |a Carbajo, A Y |e verfasserin |4 aut | |
| 700 | 1 | |a De Castro, M L |e verfasserin |4 aut | |
| 700 | 1 | |a Iborra, M |e verfasserin |4 aut | |
| 700 | 1 | |a Martin-Cardona, A |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Lago, I |e verfasserin |4 aut | |
| 700 | 1 | |a Busquets, D |e verfasserin |4 aut | |
| 700 | 1 | |a Bertoletti, F |e verfasserin |4 aut | |
| 700 | 1 | |a Ausín, M Sierra |e verfasserin |4 aut | |
| 700 | 1 | |a Tardillo, C |e verfasserin |4 aut | |
| 700 | 1 | |a Malaves, J Huguet |e verfasserin |4 aut | |
| 700 | 1 | |a Bujanda, L |e verfasserin |4 aut | |
| 700 | 1 | |a Castaño, A |e verfasserin |4 aut | |
| 700 | 1 | |a Domènech, E |e verfasserin |4 aut | |
| 700 | 1 | |a Ramos, L |e verfasserin |4 aut | |
| 700 | 0 | |a GETECCU (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa) |e verfasserin |4 aut | |
| 700 | 0 | |a Additional member of the Spanish GETECCU group |e verfasserin |4 aut | |
| 700 | 1 | |a Merino, O |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver |d 2000 |g 54(2022), 5 vom: 05. Mai, Seite 635-641 |w (DE-627)NLM108968790 |x 1878-3562 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2022 |g number:5 |g day:05 |g month:05 |g pages:635-641 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.dld.2021.10.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2022 |e 5 |b 05 |c 05 |h 635-641 | ||